Cell biology

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Retrieved on: 
Monday, January 22, 2024
Canada Research Chair, Multiple system atrophy, Patient, Biology, Emeritus, Research, Associate, Dementia, University, Neurochemistry, PMN, Cell biology, American Academy, Epitope, Vaccine, MSA, Anatomy, Physiology, Neurodegenerative disease, Microbiology, Vaccination, AAN, Immunology, PROMIS, Neuroscience, Therapy, Synucleinopathy, CAD, VIDO

“We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • “We are excited about the potential of our ground-breaking technology in neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Formulations of several of these epitopes were tested in mouse vaccination studies leading to the selection of a lead vaccine candidate for testing in mouse models replicating cognitive and motor deficits of human disease.
  • Results from the vaccination studies are being submitted for presentation at the 2024 meeting of the American Academy of Neurology (AAN) taking place from April 13-18, 2024 in Denver, Colorado.

Coherent Introduces 1000 mW Red Laser Modules for Super-Resolution Microscopy

Retrieved on: 
Thursday, January 18, 2024
Senior, Sapphire, Laser, ISO, Cell biology, DPSS, Flow cytometry, Photonics, COHR, DNA, OBIS, Coherence, SRM, SPIE, Coherent Corp.

PITTSBURGH, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a leader in lasers and thermoelectrics for life sciences and scientific research, today announced the introduction of the OBIS 640 XT, a diode-pumped solid-state (DPSS) laser module with up to 1000 mW output at 640 nm for super-resolution microscopy (SRM).

Key Points: 
  • PITTSBURGH, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a leader in lasers and thermoelectrics for life sciences and scientific research, today announced the introduction of the OBIS 640 XT, a diode-pumped solid-state (DPSS) laser module with up to 1000 mW output at 640 nm for super-resolution microscopy (SRM).
  • Innovation in visible and ultraviolet lasers is enabling breakthroughs in SRM that can resolve macromolecular structures and provide crucial new insights into cell biology.
  • Coherent introduced the OBIS 640 XT, a red laser module that matches the high output power, low noise, beam quality, and compact size of its existing portfolio of blue and green laser modules, which as a complete set enable high-performance SRM systems.
  • Coherent’s broad portfolio of products for instrumentation in life sciences also includes precision optics, filters, assemblies, and thermoelectric modules.

Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries

Retrieved on: 
Wednesday, January 17, 2024
Laser, UPF, Research, Cell biology, Flow cytometry, Biomedical Research, Knowledge, Hematology, Immunotherapy, Full Spectrum, Pompeu Fabra University, CRG, Biomarker, Doctor of Philosophy, Cell, Blood, Pharmaceutical industry

FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community.

Key Points: 
  • FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community.
  • Cytek’s collaboration serves as a testament to the substantial impact of its technology, laying the groundwork for expansion into new applications.
  • Under the terms of the agreement, Cytek will provide new, state-of-the-art spectral cytometry platforms – along with trained support personnel – to the CRG-UPF Flow Cytometry Unit’s headquarters.
  • The Unit, founded in 2001 and based in the Barcelona Biomedical Research Park, is a worldwide reference site for advanced flow cytometry applications.

Allosteric Bioscience, Inc. Signs Sponsored Research Agreement with Dr. Susan Michaelis at Johns Hopkins University for Aging/Longevity-Related Work

Retrieved on: 
Wednesday, January 17, 2024
Research, Technology, Health Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, ABI, Syndrome, Human genetics, Progeria, School, Systems biology, Johns Hopkins University, Cell biology, Molecular biology, SRA, Quantum computing, Genetics, Medical school, Normal, Ageing, Communication, Mutation, Disease, Progerin, Protein, Cell, Pharmaceutical industry

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

Key Points: 
  • Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.
  • At Johns Hopkins University Dr. Susan Michaelis will manage the analysis.
  • Dr. Michaelis is a leader in aging research and is a Professor in Cell Biology at Johns Hopkins University, School of Medicine.
  • Participation by Dr. Susan Michaelis in the SRA does not constitute or imply endorsement of Allosteric Bioscience, Inc. (Company) by Johns Hopkins University.

Calibre Scientific Acquires MoBiTec, a German Supplier of Research Tools for the Global Life Science, Diagnostic, and Pharmaceutical Industries

Retrieved on: 
Monday, January 15, 2024
Family, Research, Cell biology, IVD, Partnership, Genomics, Acquisition, Antibody, Transfection, Proteomics

MoBiTec will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for customers in the DACH region.

Key Points: 
  • MoBiTec will be integrated with BIOZOL Diagnostica GmbH, a subsidiary of Calibre Scientific, enhancing its sales capabilities and product range for customers in the DACH region.
  • MoBiTec offers research tools for the global life science, diagnostic, and pharmaceutical community.
  • “We are excited to welcome MoBiTec into the BIOZOL family,” said Jonas Bäuerle, Managing Director of BIOZOL.
  • “I am enthusiastic about our newly formed partnership with BIOZOL and the extended Calibre Scientific team.

The Rett Syndrome Research Trust Strengthens Research Team with Addition of Robert Deans as Chief Technology Officer

Retrieved on: 
Tuesday, January 16, 2024
Rubius, Therapy, MD, Knowledge, CRISPR, Rett syndrome, Cell biology, University, Science, Rett, Medicine, Parkinson's disease, IND, Regenerative medicine, Drug development, Doctor of Philosophy, RSRT, Drug, International Society, Microbiology, Pharmaceutical industry

TRUMBULL, Conn., Jan. 16, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research. Deans brings a wealth of genetic medicine knowledge and hands-on industry experience to RSRT. Most recently, he served as Chief Technology Officer of BlueRock Therapeutics, where he led the charge on stem cell and gene therapy approaches. Deans previously served as Chief Scientific Officer of Rubius Therapeutics and Executive Vice President at Athersys, where he advanced a number of stem cell therapeutics into late-stage clinical development.

Key Points: 
  • The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research.
  • Most recently, he served as Chief Technology Officer of BlueRock Therapeutics, where he led the charge on stem cell and gene therapy approaches.
  • TRUMBULL, Conn., Jan. 16, 2024 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the addition of Robert Deans, PhD, as Chief Technology Officer, Head of Research.
  • Deans' colleagues include Randall Carpenter, MD, Chief Medical Officer; Jana von Hehn, PhD, Chief Scientific Officer, Head of Clinical Development; and Monica Coenraads, Chief Executive Officer.

Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Retrieved on: 
Wednesday, January 10, 2024
Stanford University, Leukemia, Monroe Dunaway Anderson, Research, Metastasis, Ipilimumab, Cancer, Autoimmune disease, CODEX, GBM, University, National academy, Bladder cancer, MD Anderson Cancer Center, RNA, Teal, CD28, Defense, EZH2, Nobel Prize, Invention, Translational research, Health, Cell biology, Pathology, Woman, Immunotherapy, SAB, Emil Frei, Patient, Associate, MD, Roche, Burroughs Wellcome Fund, Society, FDA, ATAC, ASCI, Doctor of Philosophy, Clinical trial, Immune system, Pharmaceutical industry

Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.

Key Points: 
  • Professor Nolan will transition from his role on the Akoya Board of Directors to Chair of the SAB.
  • He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine.
  • Dr. Allison has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy.
  • This finding and a great deal of persistence paved the way for the field of immune checkpoint blockade therapy for cancer.

Element Announces Expanded Customer Base, New Products, and Unprecedented Capabilities on a Benchtop Sequencer

Retrieved on: 
Tuesday, January 9, 2024
Biology, RNA, Associate, JPM, Conference, Science, Protein, Wellcome Sanger Institute, Research, Pathology, CRISPR, DNA, Doctor of Philosophy, SAN, HD, Stanford University, Genetics, Computational biology, Trinity, Genome, Cell biology, Q50, Biological engineering, Tavarua, Pharmaceutical industry

Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.

Key Points: 
  • Achieving the fastest growth rate since launch among its peers, Element generated revenues in excess of $25 million in 2023.
  • Element CEO and Co-founder Molly He presented on the following updates to AVITI at JPM:
    Expert mode HD – Enhanced output options.
  • An instrument option that allows users to generate 20 to 70 percent more reads per run from all sequencing kits.
  • "When we launched AVITI in 2022 we redefined what is possible on a benchtop sequencer, offering an unprecedented combination of accuracy, speed, and cost.

Deepcell Announces Collaboration with NVIDIA to Accelerate Use of Generative Artificial Intelligence in Single Cell Research

Retrieved on: 
Monday, January 8, 2024
Apps, Applications, Mobile, Wireless, Technology, Software, Networks, Biotechnology, Internet, Health, Data Management, Artificial Intelligence, Developmental biology, Drug discovery, Research, Cancer, AI, Genomics, Artificial intelligence, Cell biology, Diagnosis, Intelligence, NVIDIA, Algorithm, Medical device

Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.
  • Deepcell, which already uses the NVIDIA A4000 and NVIDIA AI technology, will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology.
  • The joint collaboration aims to advance understanding of cell morphology, and ultimately accelerate the use of AI-powered cellular analysis in cell biology and translational research across a broad swath of applications including cancer, stem cell, and cell therapy.
  • “Deepcell has catalyzed the field of morpholomics and showcased the benefits of a revolutionary new method for single cell analysis using brightfield cell imaging and artificial intelligence,” said Mahyar Salek, Ph.D., Cofounder, President, and Chief Technology Officer at Deepcell.

Deepcell Achieves Key Commercial Milestones

Retrieved on: 
Monday, January 8, 2024
Technology, Research, Health Technology, Software, Biotechnology, Health, General Health, Science, Artificial Intelligence, Conference, Partnership, Federal Medical Centres, Artificial intelligence, Growth, Cell biology, Intelligence, Medical device

Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced its achievement of key commercial milestones for the REM-I platform.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced its achievement of key commercial milestones for the REM-I platform.
  • The researchers plan to use the Deepcell Human Foundation Model to identify differential cell states that occur in Alzheimer’s disease.
  • The company is in the process of manufacturing REM-I instruments to fulfill orders from diverse customers across three continents.
  • REM-I is the first platform that enables the high dimensional study of morphology using artificial intelligence, making it possible to study cellular features in ways not feasible until now,” said Marc Montserrat, Chief Business Officer at Deepcell.